Immunome/$IMNM
1D1W1MYTD1Y5YMAX
Capital at risk
About Immunome
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
- Ticker
- $IMNM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 247
- Headquarters
- Bothell, United States
- Website
- immunome.com
Immunome Metrics
BasicAdvanced
$2.7B
-
-$2.49
2.12
-
Price and volume
Market cap
$2.7B
Beta
2.12
52-week high
$30.06
52-week low
$8.93
Average daily volume
1.1M
Financial strength
Current ratio
15.077
Quick ratio
14.636
Long term debt to equity
0.009
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-257.687
Management effectiveness
Return on assets (TTM)
-37.78%
Return on equity (TTM)
-64.03%
Valuation
Price to book
5.17
Price to tangible book (TTM)
5.17
Price to free cash flow (TTM)
-10.745
Free cash flow yield (TTM)
-9.31%
Free cash flow per share (TTM)
-2.229
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-15.40%
3-year earnings per share growth (CAGR)
4.12%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Analyst projections of the future price of Immunome stock.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunome News
AllArticlesVideos
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 week ago
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire2 weeks ago
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Business Wire2 months ago
Funds containing Immunome
AllUSDEURGBP
Fund name | Fund size | $IMNM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.29% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.29% |
iShares Healthcare Innovation£DRDR | £1B | 0.29% |
iShares Ageing Population€AGED | €822M | 0.24% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.